Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIIB, Multicenter, Randomized, Parallel-Group, Open-Label Study to Evaluate the Effects of Ocrelizumab on Immune Responses in Patients With Relapsing Forms of Multiple Sclerosis

Next Previous
Trial Profile

A Phase IIIB, Multicenter, Randomized, Parallel-Group, Open-Label Study to Evaluate the Effects of Ocrelizumab on Immune Responses in Patients With Relapsing Forms of Multiple Sclerosis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ocrelizumab (Primary) ; Influenza A virus H1N1 vaccines; Influenza A virus vaccine-H3N2; Influenza B virus vaccine; Influenza virus vaccine; Keyhole limpet haemocyanin; Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal vaccine; Tetanus vaccine
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms VELOCE
  • Sponsors Roche

Most Recent Events

  • 15 Nov 2021 Status changed from active, no longer recruiting to completed.
  • 13 Sep 2021 Planned End Date changed from 13 Dec 2022 to 1 Oct 2021.
  • 22 Apr 2021 Results of an analysis reporting longer-term safety evaluations from following clinical trials: VELOCE, CHORDS, CASTING, OBOE, ENSEMBLE, LIBERTO and CONSONANCE published in the Neurology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top